The claim described an earlier position that has since changed.
Purdue said in May 2023 that the Second Circuit had upheld its plan of reorganization, which included releases of opioid claims against members of the Sackler family.
- About
- Purdue Pharma L.P.
- Claim made by
- Purdue Pharma L.P., company statement
- Published
- 30 May 2023
- Evidence score
- 94 How it was scored
- Last reviewed
- 25 October 2026
Why this label
The Second Circuit ruling, reported at 69 F.4th 45, was reversed by the US Supreme Court on 27 June 2024S3. The Court held that the bankruptcy code does not authorize a release and injunction that discharges claims against a nondebtor without the consent of affected claimantsS3. Justice Gorsuch wrote for five justices and Justice Kavanaugh dissented for fourS3. Purdue then filed a new plan. The bankruptcy court indicated on 14 November 2025 that it would approve itS4, and it entered a confirmation order on 18 November 2025S6. The 2023 plan described in the origin no longer exists as an approved plan. Only the title of the 2023 release was seen for this review.
Current procedural position
Second Circuit judgment reversed and remanded by the US Supreme Court on 27 June 2024S3. Replaced by a new plan confirmed on 18 November 2025S6.
Record supporting the assessment
69 F. 4th 45, reversed and remanded.
against a nondebtor without the consent of affected claimants.
Conflicting or limiting record
No record located that conflicts with this assessment.
Evidence score: 94 of 100
The score grades how well the record establishes this assessment. It is not a score of Purdue Pharma L.P.. Score = source authority + directness + corroboration + procedural accuracy + currency + reproducibility.
| Component | Points | Max | Reason |
|---|---|---|---|
| Source authorityIs the source competent to establish the proposition? | 30 | 30 | A Supreme Court opinion settles the validity of the releases. |
| DirectnessDoes the source state the proposition or only discuss adjacent facts? | 18 | 20 | The opinion reverses the Second Circuit ruling by citation. |
| CorroborationDo independent records support the same material point? | 12 | 15 | Purdue's 2025 release confirms a new plan replaced the old one. |
| Procedural accuracyDoes the record settle the procedural state the claim describes? | 15 | 15 | The Supreme Court ruling is final. |
| CurrencyHas the record been checked against later developments? | 10 | 10 | Checked against the May 2026 end of the bankruptcy. |
| ReproducibilityCan a reader locate the passage and repeat the assessment? | 9 | 10 | The opinion is on supremecourt.gov. |
| Total | 94 | 100 |
Timeline
Related cases
- Harrington, United States Trustee, Region 2 v. Purdue Pharma L.P.Supreme Court of the United States. Insolvency. 23-124.Stage: Decided on 27 June 2024, reversed and remanded.
- Nonconsensual third party releases not authorized, Second Circuit reversed, 5-4S3
Revision history
- Assessment first published with label Outdated.
Have a record that changes this assessment? See corrections and responses.
Sources
- S3Tier A Harrington v. Purdue Pharma L.P., No. 23-124, slip opinionSupreme Court of the United States. Court judgment. 27 June 2024.Holds that nonconsensual releases of claims against nondebtors are not authorized. It does not address the later plan.Link working, checked 25 October 2026
- S4Tier B Bankruptcy Court to Confirm Purdue Pharma’s Plan of ReorganizationPurdue Pharma L.P. via Business Wire. Company statement. 14 November 2025.Company account of the court's indication of approval and the plan amounts. It is not the confirmation order.
- S6Tier A Notice of Bankruptcy Court Order Confirming Bankruptcy Plan and Enjoining Continuation of Proceedings as to Debtor Purdue Pharma, L.P., Affiliated Debtors, and Related PartiesUS District Court for the Northern District of Ohio (notice filed by the Sackler parties in MDL No. 2804, hosted by NAAG). Court filing. 21 November 2025.Court filing that cites the confirmation order of 18 November 2025 in case 19-23649 (SHL), ECF No. 8263. It is a party notice, not the order itself.Link working, checked 25 October 2026
Other claims about Purdue Pharma L.P.
- Contradicted88Purdue's original OxyContin label said that delayed absorption from OxyContin tablets was believed to reduce the drug's abuse liability.Official report, 31 July 20074 records citedProduct claims
- Supported87The US Justice Department said Purdue Pharma pleaded guilty in November 2020 to three federal felonies tied to its opioid marketing.Regulator statement, 24 November 20202 records citedFraud
- Supported83Purdue said in November 2025 that the bankruptcy court would confirm its new plan, which provides about US$7.4 billion in cash to creditors.Company statement, 14 November 20254 records citedCorporate status